Scrip
Dendreon completes US filing for therapeutic cancer vaccine Provenge
03 November 2009
Malini Guha
Dendreon has completed its US filing for Provenge (sipuleucel-T) for advanced prostate cancer, putting the novel therapy on track for a much-anticipated FDA approval that would make it the first US-approved therapeutic cancer vaccine.
The amended BLA for the US biotech's lead product includes...
Please Login to read the full article.
03 November 2009
Malini Guha
The amended BLA for the US biotech's lead product includes...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Dendreon's Provenge prolongs prostate cancer survival in Phase III
- Sanofi-Aventis's new chemotherapy drug Jevtana improves survival in advanced prostate cancer
- Avastin fails only Phase III trial in advanced prostate cancer
- Dendreon to raise up to $448 million to fund Provenge commercialisation
COMMENT
Other Informa Comment
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
